Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JMP Securities analyst Silvan Tuerkcan upgrades Intellia Therapeutics (NASDAQ:NTLA) from Market Perform to Market Outperform...
Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of inv...
One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained t...
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine wi...
JMP Securities analyst Silvan Tuerkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) from Market Perform to Market Perform.
